Targeting NSCLC with Precision: Evaluation of the Emerging Role of Antibody-Drug Conjugates   - Episode 15

Key ADC Studies at ASCO 2024

, , , ,

Julia Rotow, MD, highlights and discusses other notable antibody-drug conjugate (ADC) data presented at the American Society of Clinical Oncology (ASCO) 2024 annual meeting, providing insights into the potential impact of these findings on the evolving treatment landscape for non-small cell lung cancer (NSCLC).

EP. 1: Treatment Strategies for NSCLC with Non-Actionable Mutations
EP. 2: Role of Antibody-Drug Conjugates in NSCLC Treatment: Insights from EVOKE-02
EP. 3: Exploring the TROPION-Lung04 Study
EP. 4: Exploring Dato-DXd Combinations as First-Line Therapy for Advanced NSCLC
EP. 5: Navigating Between ADCs in NSCLC
EP. 6: Advancing Treatment for EGFR-Mutant Advanced NSCLC: Lessons from FLAURA2
EP. 7: Osimertinib Monotherapy vs. Combination Therapy: Patient Selection in EGFR-Mutant Advanced NSCLC
EP. 8: MARIPOSA Study Insights
EP. 9: Optimizing Therapy Selection in EGFR Mutant NSCLC
EP. 10: ASCO 2024 Updates: Novel Approaches in NSCLC Therapy
EP. 11: Overview of TROP2 & Potential Role of TROP2-Directed ADCs in NSCLC
EP. 12: Key Takeaways from TROPION Trials: Implications for NSCLC Treatment Landscape
EP. 13: Targeting of HER3: Insights from HERTHENA-Lung01
EP. 14: Challenges and Learnings from EVOKE-01
Now Viewing
EP. 15: Key ADC Studies at ASCO 2024
EP. 16: Mitigating Toxicities of Dato-DXd, Sacituzumab Govitecan, and HER3-DXd
EP. 17: Patient Selection and Sequencing of NSCLC ADCs
  1. What about other ADC data being presented at ASCO 2024 this year?
    • A phase 3 global study of telisotuzumab vedotin versus docetaxel in previously treated patients with c-Met 0verexpressing, EGFR wildtype, locally advanced/metastatic nonsquamous NSCLC (TeliMET NSCLC-01).
    • ICARUS-LUNG01: A phase 2 study of datopotomab deruxtecan (Dato-DXd) in patients with previously treated advanced non-small cell lung cancer (NSCLC), with sequential tissue biopsies and biomarkers analysis to predict treatment outcome
    • Sacituzumab tirumotecan (SKB264/MK-2870) in combination with KL-A167 (anti-PD-L1) as first-line treatment for patients with advanced NSCLC from the phase II OptiTROP-Lung01 study